Table 5.

Comparison of plasma levels for the selected inflammatory molecules in subgroups of patients experiencing multiple symptoms (≥3) for intestinal acute/late toxicity. p values for test are reported.

	Acute toxicity						Late toxicity
	Patients with <3 symptoms		Patients with ≥3 symptoms		t-test		Patients with <3 symptoms		Patients with ≥3 symptoms		t-test
	Mean	SD	Mean	SD	Mean diff	p	Mean	SD	Mean	SD	Mean diff	p
CCL2 baseline	139.4	34.1	134.2	30.4	−5.2	0.75	145.5	37.3	124.9	16.5	−20.7	0.18
CCL2 50 Gy	155.7	33.9	159.7	40.9	4.1	0.83	162.4	38.5	152.3	36.7	−10.1	0.60
CCL2 end RT	161.2	20.7	165.8	42.4	4.6	0.79	165.5	39.1	161.6	28.1	−3.9	0.82
CCL2 1 mos	153.2	40.0	201.3	104.2	48.1	0.25	193.9	107.4	162.6	39.6	−31.3	0.46
IL-8 baseline	6.9	2.7	5.2	1.5	−1.7	0.15	6.4	2.6	5.4	1.6	−0.9	0.40
IL-8 50 Gy	6.6	2.5	5.4	1.9	−1.2	0.29	6.2	2.4	5.6	2.0	−0.6	0.60
IL-8 end RT	8.2	3.2	5.4	2.1	−2.8	0.06	7.6	3.1	5.4	2.3	−2.2	0.13
IL-8 1 mos	7.1	2.2	10.6	13.4	3.4	0.50	11.6	13.0	5.8	2.1	−5.8	0.25
PTX3 baseline	3.1	1.2	3.2	1.1	0.2	0.75	2.9	1.1	3.5	1.0	0.5	0.37
PTX3 50 Gy	3.3	1.5	3.1	1.1	−0.2	0.72	3.3	1.4	3.0	1.1	−0.3	0.69
PTX3 end RT	3.2	1.4	3.4	1.4	0.2	0.80	3.6	1.7	3.0	0.8	−0.6	0.40
PTX3 1 mos	3.2	1.3	3.0	1.2	−0.2	0.72	3.1	1.2	3.1	1.3	0.0	0.98
TNF alpha baseline	2.0	2.3	4.0	2.6	2.0	0.13	2.0	2.2	4.7	2.3	2.7	0.04
TNF alpha 50 Gy	2.1	2.5	3.6	3.0	1.5	0.29	2.0	2.4	4.0	3.1	2.0	0.17
TNF alpha end RT	1.9	2.3	3.3	2.4	1.3	0.27	1.9	2.2	3.7	2.3	1.8	0.14
TNF alpha 1 mos	2.3	2.3	3.8	2.3	1.5	0.23	2.5	2.6	4.1	1.8	1.6	0.17

^pg/ml for IL-1b, IL-6, CXCL8, CCL2, and TNF alpha; ng/ml: PTX3; SD: standard deviation; 1 mos: 1 month; RT: radiotherapy; diff: difference.